These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16140952)

  • 1. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
    Xu WS; Perez G; Ngo L; Gui CY; Marks PA
    Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
    J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
    Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
    Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G; Gekeler V; Leja A; Beckers T; Boehm M
    Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
    Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M
    Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
    Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
    Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
    Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
    Lobjois V; Frongia C; Jozan S; Truchet I; Valette A
    Eur J Cancer; 2009 Sep; 45(13):2402-11. PubMed ID: 19553104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
    Lee KW; Kim JH; Park JH; Kim HP; Song SH; Kim SG; Kim TY; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
    Anticancer Res; 2006; 26(5A):3429-38. PubMed ID: 17094463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
    Portanova P; Russo T; Pellerito O; Calvaruso G; Giuliano M; Vento R; Tesoriere G
    Int J Oncol; 2008 Aug; 33(2):325-31. PubMed ID: 18636153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
    Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.